Penumbra, Inc. $PEN Shares Sold by Strs Ohio

Strs Ohio lowered its position in Penumbra, Inc. (NYSE:PEN) by 16.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,306 shares of the company’s stock after selling 1,990 shares during the period. Strs Ohio’s holdings in Penumbra were worth $3,384,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in shares of Penumbra by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock worth $238,365,000 after buying an additional 18,738 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Penumbra by 1.1% in the fourth quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock valued at $198,455,000 after buying an additional 7,211 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Penumbra by 165.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock valued at $184,715,000 after buying an additional 370,636 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Penumbra by 1.5% during the fourth quarter. Janus Henderson Group PLC now owns 475,898 shares of the company’s stock worth $147,962,000 after acquiring an additional 7,050 shares during the period. Finally, Capital World Investors grew its holdings in Penumbra by 2.6% during the fourth quarter. Capital World Investors now owns 426,456 shares of the company’s stock worth $132,589,000 after acquiring an additional 10,724 shares during the period. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Analysts Set New Price Targets

PEN has been the subject of a number of recent analyst reports. Zacks Research downgraded Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Penumbra in a research note on Monday. Citigroup cut their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $360.33.

Penumbra Price Performance

NYSE PEN traded up $0.85 during mid-day trading on Tuesday, hitting $319.08. The stock had a trading volume of 46,218 shares, compared to its average volume of 733,928. The company has a 50 day simple moving average of $321.32 and a 200 day simple moving average of $329.68. The company has a market cap of $12.55 billion, a price-to-earnings ratio of 73.56, a P/E/G ratio of 1.97 and a beta of 0.70. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The firm had revenue of $374.76 million for the quarter, compared to analysts’ expectations of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.83 earnings per share. Equities analysts forecast that Penumbra, Inc. will post 5.04 EPS for the current fiscal year.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.